Clinical Trial Update: Belatacept to Prevent Organ Rejection in Kidney Transplant Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating belatacept to prevent rejection in kidney transplant patients was terminated, and results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Rejection

Drugs mentioned

• Nulojix (belatacept)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Renal Transplant | Phase 2 | Status: TERMINATED | Results posted: 2011-11-07